Abstract
Abstract Background: To compare the effects ofthree types of sulfonylureas (glibenclamide, gliclazide, and glimepiride) on blood plasminogen activator inhibitor-1 levels in patients with type2 diabetes mellitus, a
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have